Nucleix’s non-invasive Bladder EpiCheck biomarker test allows for personalized monitoring of bladder cancer
Prof. Shahrokh F. Shariat: “Using Bladder EpiCheck as a rule-out test, can reduce 80% of cystoscopies without missing a single high-grade cancer”. REHOVOT, Israel, Feb. 21, 2019 /PRNewswire/ — Nucleix Ltd., a leading cancer detection and screening company, announced today that Bladder EpiCheck™, its biomarker-based non-invasive urine test for the detection of non‐muscle invasive bladder cancer (NMIBC), was shown to be an effective rule-out test for NMIBC recurrence, thereby minimizing the need for invasive cystoscopies.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.